MedMira Completes Settlement of Debt

About this update from Medmira Inc.

[{"type":"text","content":"\n\n\n\nHALIFAX, Sept. 2 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,\nNASDAQ: MMIRF) a developer and marketer of rapid diagnostics, announced today\nthat it has reached an agreement with debt holders to settle a total of\n$100,383 owing for debts to the Company through the issuance of common shares.\nThe Company will issue 818,118 common shares at a price of $0.1227 per share\ncalculated as a discount on the previous 10 day volume weighted average price.\nThis agreement is subject to the approval of the TSX Venture Exchange. Shares\nissued under this agreement will be subject to mandatory four month hold\nperiod.\n\n\nAbout MedMira\n\n\nMedMira is a leading developer and manufacturer of flow-through rapid\ndiagnostics. The company's tests provide hospitals, labs, clinics and\nindividuals around the world with reliable, rapid diagnosis for diseases such\nas HIV and hepatitis C in just three minutes. The company's tests are sold\nunder the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in\nglobal markets. MedMira's rapid HIV test is the only one in the world to\nachieve regulatory approvals in Canada, the United States, China and the\nEuropean Union.\n\n\nThe company's corporate offices and manufacturing facilities are located\nin Halifax, Nova Scotia, Canada with a representative office in China. For\nmore information visit MedMira's website at www.medmira.com.\n\n\nThis news release contains forward-looking statements, which involve risk\nand uncertainties and reflect the company's current expectation regarding\nfuture events. Actual events could materially differ from those projected\nherein and depend on a number of factors including, but not limited to,\nchanging market conditions, successful and timely completion of clinical\nstudies, uncertainties related to the regulatory approval process,\nestablishment of corporate alliances and other risks detailed from time to\ntime in the company quarterly filings.\n\n\nThe TSX Venture Exchange has not reviewed and does not accept\n\n\nresponsibility for the adequacy or accuracy of this statement.\n\n\n%SEDAR: 00013053E\n\n\n","length":2186,"tagName":"div"}]

More updates from Medmira Inc.